Scientists discover first new class of antibiotics that could fight off drug-resistant bacteria
ADVERTISEMENT
Researchers say they have discovered a new class of antibiotics that could treat drug-resistant bacteria, the first to reach the market in nearly three decades.
The new molecule, called lariocidin, works by targeting a part of a bacteria's cell called the ribosome and can disrupt the cell's functions.
"This is a new molecule with a new mode of action. It's a big leap forward for us," Gerry Wright, a professor at McMaster University in Canada and one of the corresponding authors of the study, said in a statement.
Related
Microplastics may make bacteria more resistant to antibiotics, researchers say
Researchers discovered it by growing bacteria from soil in a backyard for approximately one year, according to their findings published in the journal
Nature
.
They found that lariocidin is produced by the Paenibacillus bacteria, which was found in the soil.
The researchers exposed the samples to E. coli, a common gut bacterium with strains that can cause serious disease.
In addition to its action against bacteria, lariocidin also showed no toxicity to human cells.
"Lariocidin has a broad spectrum of action as it is effective against both Gram-positive and Gram-negative bacteria, including those identified as priorities by the World Health Organisation in the search for new antimicrobials due to their multi-drug resistance profile," Rafael Cantón, head of the microbiology department at the Madrid-based Ramón y Cajal Hospital, said in a statement.
Cantón, who didn't take part in the study, also highlighted that the discovery of a completely new mechanism to target pathogens represents a "milestone in the fight against resistant bacteria".
More research, including clinical trials, is necessary to confirm the compound's efficacy.
Related
Scientists discover the first new antibiotics in over 60 years using AI
Antimicrobial resistance: a growing concern for public health
The World Health Organization (WHO) has said that antimicrobial resistance (AMR) is one of the top global public health threats.
"Our old drugs are becoming less and less effective as bacteria become more and more resistant to them," Wright said.
According to the WHO, around 4.95 million deaths globally are associated with AMR.
In Europe and Central Asia, antimicrobial resistance causes 133,000 deaths each year, WHO's regional office in Europe has said.
It has also been estimated to cost the European Union and Economic Area around €11.7 billion yearly due to productivity loss and healthcare expenditure.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
LeMonde
a day ago
- LeMonde
UNOC: The mining industry's growing appetite for the ocean floor drives debate at UN ocean conference
Will the polymetallic nodules – valuable rocks containing rare metals – that rest on the abyssal plains remain at the bottom of the ocean, and for how much longer? At the One Ocean Science Congress, which brought together more than 2,000 scientists from June 3 to 6 ahead of the United Nations Ocean Conference (UNOC), this question weighed heavily on the minds of many researchers. Mining rare minerals from the deep ocean could have serious consequences for these largely unknown ecosystems. Yet, pressure for the commercial exploitation of these resources – which could be used to manufacture batteries, for example – has been mounting, notably from the mining industry. Canada-based The Metals Company has grown impatient with the slow pace of negotiations that have dragged on for a decade within the International Seabed Authority (ISA). Under the United Nations Convention on the Law of the Sea, the international organization is tasked with regulating the exploitation of the "Zone" – the seabed and subsoil in international waters, which do not belong to any state. Finalizing a mining code has proven particularly challenging, given the sharp disagreements among delegations. Some countries are eyeing these oceanic resources, while a group of about 30 states is calling for a moratorium – a "precautionary pause" – or even a ban, as is the case with France.
Euronews
2 days ago
- Euronews
L'Oréal acquires a majority stake in British skincare brand Medik8
L'Oréal has acquired a majority stake in the UK's Medik8 as it seeks to expand its position in the skincare market, the French beauty giant confirmed on Monday. As part of the deal, private equity firm Inflexion will remain a minority shareholder, and the current management committee will also stay in their roles. The cost of the stake is officially undisclosed, although the Financial Times reported last week that the potential deal was worth around €1bn. L'Oréal's share price was roughly unchanged on the news. 'We are delighted to welcome Medik8 to the L'Oréal family,' said Cyril Chapuy, President of L'Oréal LUXE. 'As a premium skincare range, with high levels of proven efficacy at an accessible price point, Medik8 perfectly complements our existing skincare portfolio,' he added. L'Oréal has been seeking to capitalise on the boom in science-driven skincare, partly driven by social media influencers. Brands already under its 'Dermatological Beauty Division' include La Roche-Posay, Cerave, Vichy, Skinceuticals, and Skinbetter Science. This unit brought in over €7bn in revenue in 2024, representing an almost 10% year-on-year rise, making it L'Oréal's fastest-growing division. Seeking to expand its portfolio, L'Oréal bought soap maker Aesop in 2023, and Korean beauty brand Dr.G in December. Last year, L'Oréal also acquired a 10% stake in skincare firm Galderma, as well as acquiring the beauty licence for Miu Miu. At the time of the Galderma deal, the French firm said it was 'increasingly investing in a more holistic approach, spanning the entire beauty routine' — thereby 'anticipating and intercepting the signs of skin ageing'. Medik8, founded in 2009, specialises in anti-ageing treatments and was bought by UK-based private equity firm Inflexion in 2021. Media conglomerate Warner Bros. Discovery announced on Monday that it would split into two public companies by next year, carving off its TV network operations from its streaming service. The move to spin off one company devoted to streaming and a second devoted to traditional television comes as the company struggles with a decline in overall business. The organisation said the new Streaming & Studios group would include Warner Bros. Television, Warner Bros. Motion Picture Group, DC Studios, HBO and HBO Max as well as their film and television libraries. The Global Networks company will include CNN, TNT Sports, Discovery+ and other digital products. Shares in the company jumped more than 9% ahead of the market opening. Current Warner Bros. Discovery CEO David Zaslav will continue as the head of Streaming & Studios, while the company's chief financial officer Gunnar Wiedenfels will become CEO of Global Networks. Both executives will continue in their current positions until the company separates. 'By operating as two distinct and optimised companies in the future, we are empowering these iconic brands with the sharper focus and strategic flexibility they need to compete most effectively in today's evolving media landscape,' Zaslav said in a statement. The US media giant said the split would unlock value for shareholders and create opportunities for both businesses. The split still needs final approval from the company's board but is expected to be completed by the middle of next year. Warner Bros. Discovery was created only three years ago after a merger between Warner Media and Discovery.
Fashion Network
2 days ago
- Fashion Network
L'Oreal expands dermatological skincare portfolio with Medik8 deal
L'Oreal will acquire British skincare brand Medik8, Britain-based private equity firm Inflexion said on Monday, as the French cosmetics giant boosts its offering in the fast-growing dermatological skincare market. Neither party disclosed the size of the deal. Medik8 produces vitamin A-based anti-aging creams and serums. "The partnership with L'Oreal will allow Medik8 to deepen its presence in existing markets and expand globally. As part of the transaction, Inflexion will retain a minority shareholding in Medik8," the private equity firm said in a statement. L'Oreal's dermatological beauty division, which includes major brands like CeraVe, La Roche-Posay and SkinCeuticals, has remained its fastest-growing unit in recent years. The division generated 7 billion euros ($7.99 billion) in revenue last year, marking a growth of nearly 10% compared to the previous year. The business also delivers the highest profit margin among L'Oreal's four divisions. Consumer interest in science-backed products has driven the division's growth, though rising competition has recently slowed that momentum. L'Oreal executives said this year they are pursuing acquisitions to revive slowing growth. The company acquired Korean skincare brand Dr.G in December and also bought a minority stake in Oman-based perfume house Amouage last year. ($1 = 0.8757 euros)
